Major Institutional Investor Sells $173.7M in Kymera Therapeutics Shares
KYMR has more than doubled off its 52-week low of $36.65 on elevated volume (5.7× avg).
Summary
A major institutional investor group, Biotechnology Value Fund, has significantly reduced its stake in Kymera Therapeutics by selling $173.7 million worth of shares, representing a substantial portion of their prior holdings.
Key Events · Ownership and Investor Activity · KYMR
-
Significant Share Sale by Institutional Investor
Biotechnology Value Fund (BVF) and its affiliates sold 1,630,658 shares of Kymera Therapeutics common stock at $106.50 per share, totaling approximately $173.7 million.
-
Substantial Reduction in Stake
This transaction represents a reduction of over 23% of BVF's prior holdings in the company, with the group's aggregate ownership now at 6.3% of outstanding shares.
-
Large Market Impact
The sale value of $173.7 million is a significant amount, representing nearly 2% of Kymera Therapeutics' total market capitalization.
Analysis · KYMR · Life Sciences
Biotechnology Value Fund (BVF) and its affiliates, a significant institutional investor group, have sold a substantial portion of their holdings in Kymera Therapeutics. This sale of $173.7 million represents nearly 2% of the company's market capitalization and over 23% of BVF's prior stake, indicating a significant reduction in their position. While institutional investors often rebalance portfolios, a sale of this magnitude and proportion of their holdings by a long-term investor group can be interpreted as a loss of conviction or a strategic shift.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1052 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KYMR was trading at $108.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.9B. The 52-week trading range was $36.65 to $130.05. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.